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was not an efficacy study, but rather a pharmacokinetics
and safety study of zidovudine (An) and lamivudine (3TC)
for 14 days in 20 mothers in late pregnancy, and in their
neonates for a week. The lower rate of mother-to-infant
transmission in a study of 20 women in comparison with the
vertical transmission rate in a retrospective cohort study
cannot be used as argument for the routine use of
antiretroviral therapy in HIV-positive pregnant women.
The World Health Organisation and the Joint United
Nations Programme on HIV/AIOS (UNAIOS) have recognised
that the ACTG 076 regimen is not applicable in those parts of
the world where most mother-to-infant transmissions occur,
and have called for placebo-controlled trials as the best
option for obtaining rapid and scientifically valid results.
These trials should include antiretroviral agents given for short
durations in late pregnancy, in labour, and to neonates for 1
or 2 days; oral therapy in labour only; and combinations of
different antiretroviral drugs. An ongoing trial, PETRA
(perinatal transmission), supported by UNAIOS but designed
in conjunction with African scientists, is currently in progress
in a number of African centres, including Durban and
Johannesburg. The aim of this placebo-controlled trial is to
evaluate whether shorter regimens, which can realistically be
implemented in test countries, are better than no treatment at
all. Subanalysis of the ACTG 076 study has shown that less
than 12-week regimens are as effective as those of more than
12 weeks. This, however, does not give any indication of the
efficacy of a 2 - 3-week regimen.
Another debatable issue not included in the article by
Matchaba and Chapanduka but that needs to be mentioned
is the ethical considerations of placebo-controlled trials in
developing countries.' Critics maintain that nearly all such
trials violate accepted international ethical standards
because participating control groups are only offered
placebos, as opposed to being given antiretroviral therapy
that is known to be effective.
The debate has led to comparisons with the Tuskegee
study, in which effective treatment was withheld from some
400 African Americans without their knowledge in order to
establish the natural history of syphilis. This study has been
described as a 'metaphor for racism in medicine.'
Comparison with vertical transmission HIV studies in
pregnancy, however, is unfair. Trials in Africa are frequently
conducted by African scientists who have contributed
significantly to the design of the studies and who are
concerned for the welfare of their particular communities. In
addition, local government authorities are informed of all
such studies and ethical permission, usually from university
ethical committees, will have been obtained. Subjects are
informed of the existence of a placebo arm and give written
consent. They are not intentionally deceived or deprived of
treatments that are affordable, readily available and known
to be effective, as was the case in the Tuskegee experiment.
Placebo-controlled antiretroviral trials in developing
countries will continue until a short applicable regimen is
found to be effective in reducing mother-to-infant
transmission.
The level of information provided to participant women
and consent procedures are two further criticisms of these
studies. Certainly in the trials conducted in South Africa,
women were fully informed regarding the benefits and
disadvantages involved, including the placebo component.
Criticism of HIV trials in developing countries has raised
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the question of whether these studies could be undertaken
in the First World. The question of double standards,
however, lies not in the way the trials are being conducted,
but in unequal access to medicines in different countries.
It is our conclusion that before demands are made for the
immediate use of antiretrovirals in pregnancy, an interaction
is urgently needed between researchers, health authorities,
pharmaceutical companies and global institutional
programmes such as UNAIOS. This interaction would help
prepare the infrastructure for the application of a short and
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Preventing perinatal HIV
transmission - now is the
time to act!
We thank Moodley et al. for their response to our paper.'
We are pleased to note that they concur that the major
intervention in the prevention of perinatal HIV transmission is
AZT use. In our paper we stated the need for the
development of local protocols, outlined the reasons for this
and certainly did not recommend that protocol ACTG 0762
be used here. We believe that all the 'realities of the situation
in respect of health care in developing countries' referred to
by Moodley et al. in their response were SUfficiently
addressed in our original paper. The breast-feeding issue
was also addressed at length.
They seem, however, to have missed two important issues
raised by ourselves. Instead they focused on the issue of
placebo-controlled trials, which we elected not to raise in
our editorial' because of the volatile nature of the topic. We
did not want to distract from the main thrust of our editorial,
namely that 'now is the right time to act' in dealing with
perinatal HIV transmission using zidovudine (AZT) as part of
the national maternal and child health care (MCHC)
programme. We will, however, address the issue of placebo
trials in perinatal HIV transmission later in this article.
. The first point they overlooked was the length of time it is
taking to get protocols or interim results from the local
studies being done. During this time perinatal transmission
of HIV continues unabated.
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The ACTG 076 study commenced in 1993 in the USA and
France, where the first scheduled interim analysis was
carried out on 364 mother/child pairs. On 17 February 1994,
on the basis of an interim analysis, the independent Data
and Safety Monitoring Board overseeing ACTG 076
determined that there was significant efficacy (67.5%
relative reduction in transmission), and recommended that
enrolment into the study be terminated and all women under
study be offered AZT. The speed with which the study was
performed in countries with an HIV-positive antenatal
seroprevalence rate of only 0.1 % is to be commended.
Accordingly, in 1997 there was a reduction in paediatric
AIDS cases in the USA for the first time. The reverse
appears to be the case in Third-World communities where
the rate of HIV seropositivity at antenatal clinics is bordering
on 30%. We wonder how many readers are aware of the
PETRA trial sponsored by the Joint United Nations
Programme on HIV/AIDS (UNAIDS), the protocols used, etc.,
and that this trial was commissioned in 1995.
Three years later we are still waiting for the results of the
first interim analysis to be published. The idealism of waiting
for the scientifically perfect paper when interim results could
possibly confirm a significant clinical breakthrough cannot
be condoned in the face of an issue of such public
importance.
The second issue Moodley et al. appear to have missed is
our point that offering no treatment as an alternative, for
whatever reason, is 'penny wise and pound foolish'. In the
long run more money is spent dealing with paediatric AIDS.
The assertion that there are other priorities in developing
countries which have led to continued shrinkage of health
care budgets further supports our belief that these countries
are pursuing self-defeatist policies by not preventing HIV
perinatal transmission. In South Africa we have witnessed
the effects of a shrinking health budget. Sadly this is largely
due to central government maintaining a tight monetary and
fiscal policy, as dictated by the policy of growth,
employment and reconstruction (GEAR). The idea underlying
the implementation of GEAR was that bodies such as the
International Monetary Fund, the World Bank and other
private foreign investors would invest in South Africa,
creating jobs and economic growth. This is not the forum to
debate the merits or demerits of GEAR, but we warn that
similar programmes implemented elsewhere in developing
countries have resulted in a shameful deterioration of health
care. If a foreign army were to invade this country, possibly
incapacitating 30% of its economically active population,
would the government not respond with all the military and
economic might at its disposal? The fact that this invasion is
being accomplished by a virus is overlooked when it comes
to health budget allocations. Cost, as we stated previously,
is a relative concept.
We will now address the issue that Moodley et al. spent
considerable time on, namely placebo-controlled trials in
developing countries, including South Africa. Our position is
clear: they are both scientifically and morally unjustifiable.
When one considers the results of ACTG 076, it does not
make scientific sense to substitute the currently accepted
'gold standard' (ACTG 076) with a no-treatment placebo
arm. We appreciate the use of trials with shorter
AZT/lamivudine (3TC) dosage schedules. These make sense
in terms of cost, the fact that the major transmission of HIV
is peripartum, and because there is less chance of inducing
viral resistance this way. However, at research level the
control must be ACTG 076. In the end each country must
decide what percentage decrease in vertical transmission
they are willing to settle for in terms both of cost and
perinatal mortality rate. To suggest that a no-treatment!
placebo arm at research level is still justifiable on the
grounds that most of the patients concerned would not be
on treatment anyway, is to miss the point that we are at
pains to make, namely that the no-treatment option will cost
more later. This is besides the moral implications. The fact
that these trials are being conducted by 'African scientists'
does not give them the moral or scientific high ground.
These 'African scientists' have, through no fault of their own,
failed to influence their governments' expenditure on health
and research. If truth be told, Africans and Asians could
have done more to prevent the spread of HIV, which has
been met with denial, procrastination and bungling. From a
public health point of view this has been a disaster. Will we
again miss the chance to act decisively when it comes to
perinatal transmission? For African scientists to try to
politicise criticism of placebo trials as intervention from the
West is wrong. Rather, they must convince their
governments to spend more money on combating HIV, and
less on defence.
At a recent conference on 'Global strategies for the
prevention of HIV transmission from mothers to infants'
(3 - 6 September 1997, Washington, DC, USA), Or Gayle
from the Centers for Disease Control commented on the
issue of placebo trials: 'Acceptance of this tragedy as a
reality that cannot be changed is not acceptable morally, not
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The Tamil New Year
Veguthan~
is to be celebrated
on 14 April 1998.
We extend our good wishes
to South Africa's
Tamil community at this time.
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